about
Predictive factors of late venous aortocoronary graft failure: ultrastructural studies.Silane-modified surfaces in specific antibody-mediated cell recognition.Histological evaluation of age-related variations in saphenous vein grafts used for coronary artery bypass grafting.Preexisting high expression of matrix metalloproteinase-2 in tunica media of saphenous vein conduits is associated with unfavorable long-term outcomes after coronary artery bypass grafting.Peritoneal mesothelium promotes the progression of ovarian cancer cells in vitro and in a mice xenograft model in vivo.Cytokeratin 8 in venous grafts: a factor of unfavorable long-term prognosis in coronary artery bypass grafting patients.Preoperative factors predicting saphenous vein graft occlusion in coronary artery bypass grafting: a multivariate analysis.Evaluation of cardiac muscle microvessel density in children diagnosed with cyanotic heart defects.Late subclinical hemolysis and long-term outcomes after aortic valve replacement with On-X mechanical prostheses - a preliminary single-center report.Caveolin 2: a facultative marker of unfavourable prognosis in long-term patency rate of internal thoracic artery grafts used in coronary artery bypass grafting. Preliminary report.Potentially positive ageing-related variations of medial smooth muscle cells in the saphenous veins used as aortocoronary bypass grafts.Characteristics of age-related changes in rat thymus: morphometric analysis and epithelial cell network in various thymic compartments.Homing of hemopoietic precursor cells to the fetal rat thymus: intercellular contact-controlled cell migration and development of the thymic microenvironmentCD105 and placental growth factor--potent prognostic factors in childhood acute lymphoblastic leukaemiaEndothelial integrity of radial artery grafts harvested by minimally invasive surgery--immunohistochemical studies of CD31 and endothelial nitric oxide synthase expressions: a randomized controlled trialAssociation between small fiber neuropathy and higher skin accumulation of advanced glycation end products in patients with type 1 diabetes
P50
Q34935520-E3079358-8DAB-41F3-9AB0-1C3AF362A738Q35325417-1D5FD97A-B36E-4443-8E46-05B3EB7D6B1EQ36524851-127C1417-48B1-42F8-8CE4-B13BDC0058DAQ37208634-DE59B7CA-15E6-4BEA-B00B-1ACC86200650Q38949227-DA98C874-61B2-4931-8141-DEEF16358026Q39294804-ED73E2A4-7121-45AA-A3C2-726F09839C30Q42263880-27E89AFA-7C31-42F7-A5C8-1DF537657ECCQ45749214-A1F92120-99D8-40BB-B036-BF8EBE340E0BQ47109564-E3FD7509-7E13-41A9-8C0C-0EBC5D571F60Q50692187-227FCBBB-A790-447B-B708-8A9857F9D60EQ51326821-9772D859-D0C7-4DD1-B4CD-BAF955CF6927Q51727123-9FD31D5D-3548-4089-B5D1-09ECBA18E3D0Q81140876-3C10172F-D227-41FE-AFC3-052B3ACE52A1Q83876152-D8C7F3A3-285A-4B57-96F3-71AB75F6E8C0Q85048698-8C0C4EA6-8BB8-4F71-8BE6-646DCFB24CA1Q88888401-732AD581-D942-4F7B-A15B-0F03D05C2319
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Agnieszka Malinska
@ast
Agnieszka Malinska
@en
Agnieszka Malinska
@es
Agnieszka Malinska
@nl
Agnieszka Malinska
@sl
type
label
Agnieszka Malinska
@ast
Agnieszka Malinska
@en
Agnieszka Malinska
@es
Agnieszka Malinska
@nl
Agnieszka Malinska
@sl
prefLabel
Agnieszka Malinska
@ast
Agnieszka Malinska
@en
Agnieszka Malinska
@es
Agnieszka Malinska
@nl
Agnieszka Malinska
@sl
P106
P1153
22985841700
P21
P214
2217152684008523430006
P31
P496
0000-0001-8696-8845
P7859
viaf-2217152684008523430006